What is Interspond?
Founded in 2003, Interspond operates as a Trial Management Organization, building upon a business model established by its founder, Kathy S. Cox, who pioneered one of the industry's first TMOs in 1996. The company specializes in identifying clinical trial opportunities for research sites and streamlining the study start-up process. Interspond collaborates with multi-therapeutic sites nationwide, recently expanding its hybrid model to include exclusive business development services for a network of neurology, rheumatology, and ophthalmology sites. For sponsors and CROs, Interspond provides substantial value by rapidly identifying qualified sites for Phase 2 through 4 studies, managing the execution of Confidentiality Disclosure Agreements (CDAs), feasibility questionnaires (FQs), pre-study site visits (PSSVs), regulatory document submissions, and contract/budget negotiations. The company also manages site payments and reconciles study finances.
How much funding has Interspond raised?
Interspond has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Interspond
PPP
Public-Private Partnership
What's next for Interspond?
The recent major strategic investment positions Interspond for continued growth and expansion within the competitive clinical trial management sector. As a late-stage company, this capital infusion is likely to be directed towards enhancing its hybrid business model, potentially broadening its network of exclusive and affiliated sites, and further solidifying its partnerships with sponsors and CROs. The company's focus on operational efficiency and site qualification suggests a strategic direction aimed at capturing a larger share of the market by offering a robust and reliable service for clinical trial execution.
See full Interspond company page
